intellim Holdings opens European headquarters

TOKYO, Japan, November, 2019 – intellim Holdings Corporation, (President & CEO: Masakuni Ukita, Tokyo, JAPAN) a leading Clinical Research Organization has opened its European headquarters in Helmond, The Netherlands. The opening of intellim Europe B.V. will enable intellim to serve the exponential growth of Asia-based pharmaceutical manufacturers entering Europe. intellim Europe B.V. will also act as the contact point for European pharmaceutical and medical device manufacturers entering the Asian market. The opening of intellim Europe B.V. is another phase in its global expansion.

About intellim Holdings

Tokyo based intellim Holdings is Asia’s fastest growing Clinical Research Organizations with capabilities in Japan, South Korea, Malaysia, Thailand and China. Founded in 2005, the intellim Group provides world class regulatory consulting and clinical research monitoring services. intellim’s experience in multi-national trials in the areas of regenerative medicine, oncology, and other life impacting therapies have contributed to its ongoing growth. The intellim Group’s highly qualified multi-lingual personnel is capable of providing pharmaceutical and medical device manufacturers the expertise they require to navigate the global pathways of clinical trials.

Address	：	Steenovenweg 5, 5708 HN Helmond, The Netherlands